Slingshot members are tracking this event:
First Patient Enrolled in Bayer (BAYRY) and Merck's (MRK) Phase 3 VICTORIA Trial Assessing Vericiguat in Chronic Heart Failure Without Reduced Ejection Fraction
Slingshot Insights Explained
Sep 28, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Victoria Trial, Vericiguat, Chronic Heart Failure, Reduced Ejection Fraction